Tags

Type your tag names separated by a space and hit enter

Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives.
Indian J Med Res. 2019 06; 149(6):706-714.IJ

Abstract

Onchocerciasis and lymphatic filariasis (LF) are human filarial diseases belonging to the group of neglected tropical diseases, leading to permanent and long-term disability in infected individuals in the endemic countries such as Africa and India. Microfilaricidal drugs such as ivermectin and albendazole have been used as the standard therapy in filariasis, although their efficacy in eliminating the diseases is not fully established. Anti-Wolbachia therapy employs antibiotics and is a promising approach showing potent macrofilaricidal activity and also prevents embryogenesis. This has translated to clinical benefits resulting in successful eradication of microfilarial burden, thus averting the risk of adverse events from target species as well as those due to co-infection with loiasis. Doxycycline shows potential as an anti-Wolbachia treatment, leading to the death of adult parasitic worms. It is readily available, cheap and safe to use in adult non-pregnant patients. Besides doxycycline, several other potential antibiotics are also being investigated for the treatment of LF and onchocerciasis. This review aims to discuss and summarise recent developments in the use of anti-Wolbachia drugs to treat onchocerciasis and LF.

Authors+Show Affiliations

Department of Medicine, Faculty of Medicine & Health Sciences; Laboratory of Medical Gerontology, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia.Liverpool Brain Infection Group, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.Department of Surgery, Faculty of Medicine & Health Sciences; Laboratory of Medical Gerontology, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia.Laboratory of Medical Gerontology, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia.Department of Family Medicine, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.Department of Medicine, Faculty of Medicine & Health Sciences, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia.Department of Medicine, Faculty of Medicine & Health Sciences, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia.Department of Medicine, Faculty of Medicine & Health Sciences; Laboratory of Medical Gerontology, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia.Department of Medicine, Faculty of Medicine & Health Sciences, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia.Department of Medicine, Faculty of Medicine & Health Sciences; Laboratory of Medical Gerontology, Malaysian Research Institute on Ageing, Universiti Putra Malaysia, Serdang, Malaysia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31496523

Citation

Wan Sulaiman, Wan Aliaa, et al. "Anti-Wolbachia Therapy for Onchocerciasis & Lymphatic Filariasis: Current Perspectives." The Indian Journal of Medical Research, vol. 149, no. 6, 2019, pp. 706-714.
Wan Sulaiman WA, Kamtchum-Tatuene J, Mohamed MH, et al. Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives. Indian J Med Res. 2019;149(6):706-714.
Wan Sulaiman, W. A., Kamtchum-Tatuene, J., Mohamed, M. H., Ramachandran, V., Ching, S. M., Sazlly Lim, S. M., Hashim, H. Z., Inche Mat, L. N., Hoo, F. K., & Basri, H. (2019). Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives. The Indian Journal of Medical Research, 149(6), 706-714. https://doi.org/10.4103/ijmr.IJMR_454_17
Wan Sulaiman WA, et al. Anti-Wolbachia Therapy for Onchocerciasis & Lymphatic Filariasis: Current Perspectives. Indian J Med Res. 2019;149(6):706-714. PubMed PMID: 31496523.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives. AU - Wan Sulaiman,Wan Aliaa, AU - Kamtchum-Tatuene,Joseph, AU - Mohamed,Mohd Hazmi, AU - Ramachandran,Vasudevan, AU - Ching,Siew Mooi, AU - Sazlly Lim,Sazlyna Mohd, AU - Hashim,Hasnur Zaman, AU - Inche Mat,Liyana Najwa, AU - Hoo,Fan Kee, AU - Basri,Hamidon, PY - 2019/9/10/entrez PY - 2019/9/10/pubmed PY - 2020/2/27/medline KW - Black flies KW - Wolbachia KW - doxycycline KW - filariasis KW - lymphatic filariasis KW - macrofilaricides KW - minocycline onchocerciasis SP - 706 EP - 714 JF - The Indian journal of medical research JO - Indian J Med Res VL - 149 IS - 6 N2 - Onchocerciasis and lymphatic filariasis (LF) are human filarial diseases belonging to the group of neglected tropical diseases, leading to permanent and long-term disability in infected individuals in the endemic countries such as Africa and India. Microfilaricidal drugs such as ivermectin and albendazole have been used as the standard therapy in filariasis, although their efficacy in eliminating the diseases is not fully established. Anti-Wolbachia therapy employs antibiotics and is a promising approach showing potent macrofilaricidal activity and also prevents embryogenesis. This has translated to clinical benefits resulting in successful eradication of microfilarial burden, thus averting the risk of adverse events from target species as well as those due to co-infection with loiasis. Doxycycline shows potential as an anti-Wolbachia treatment, leading to the death of adult parasitic worms. It is readily available, cheap and safe to use in adult non-pregnant patients. Besides doxycycline, several other potential antibiotics are also being investigated for the treatment of LF and onchocerciasis. This review aims to discuss and summarise recent developments in the use of anti-Wolbachia drugs to treat onchocerciasis and LF. SN - 0971-5916 UR - https://www.unboundmedicine.com/medline/citation/31496523/Anti_Wolbachia_therapy_for_onchocerciasis_&_lymphatic_filariasis:_Current_perspectives_ DB - PRIME DP - Unbound Medicine ER -